PaulRConklingMD

Oncology • Norfolk, VA

Physician

Join to view full profile

Dr. Conkling is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Conkling's full profile

Already have an account?

Office
5900 Lake Wright Dr
Norfolk, VA 23502
Phone+1 757-466-8683

Fax+1 757-213-5846
Is this information wrong?

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1985 - 1988
Duke University HospitalResidency, Internal Medicine, 1982 - 1985
Ohio State University College of MedicineClass of 1982

Certifications & Licensure

VA State Medical License 1988 - 2026
NC State Medical License 1984 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Top MD Consumers Checkbook
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
Completed
Phase 3
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
Completed
Phase 1
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
Completed
Phase 1, Phase 2
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
Completed
Phase 1
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09
Terminated
Phase 1
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
Terminated
Phase 1, Phase 2
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors Start of enrollment: 2017 Dec 06
Active, not recruiting
Phase 1, Phase 2
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies Start of enrollment: 2018 Oct 15
Completed
Phase 1
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer Start of enrollment: 2019 Apr 01
Active, not recruiting
Phase 1
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer Start of enrollment: 2019 Dec 10
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

7 citations
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage sm...
Chao Li, Lowell L. Hart, Taofeek K. Owonikoko, Raid Aljumaily, Caio Max Sao Pedro Rocha Lima, Paul Conkling, Roy Timothy Webb, Robert M. Jotte, Steven R. Schuster, Wil...> ;Cancer Chemotherapy and Pharmacology. 2021 Feb 17
36 citations
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John D. Powderly, Lauren C. Harshman, Paul Conkling, Jean-Pierre Delord, Michael S. Gordon, Joseph K...> ;Clinical Cancer Research. 2021 Feb 10
52 citations
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Aditya Bardia, Virginia G. Kaklamani, Sharon Wilks, Amy Weise, Donald A. Richards, Wael A. Harb, Cynthia Osborne, Robert Wesolowski, Meghan Sri Karuturi, Paul Conkling...> ;Journal of Clinical Oncology. 2021 Jan 29
8 citations
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluor...
Tracy Murray Stewart, Daniel D. Von Hoff, Michael L. Fitzgerald, Laurence J. Marton, Thomas E. Boyd, Paul Conkling, Lawrence Garbo, Robert M. Jotte, Donald A. Richards...> ;Cancer Chemotherapy and Pharmacology. 2021 Jan 1
12 citations
Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer
Anne C. Chiang, Lecia V. Sequist, Jill Gilbert, Paul Conkling, D. S. Thompson, J. Paul Marcoux, Scott N. Gettinger, Marcin Kowanetz, Luciana Molinero, Carol O'Hear, Ma...> ;Clinical Lung Cancer. 2020 May 12
21 citations
Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.
Steven J. Isakoff, Josep Tabernero, L. R. Molife, J-C. Soria, Andrés Cervantes, Nicholas J. Vogelzang, Manish R. Patel, Maha Hussain, Ari David Baron, Guillem Argiles,...> ;Annals of Oncology. 2020 May 1
813 citations
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;The Lancet. Oncology. 2020 Feb 1
108 citations
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
Shirish M. Gadgeel, Rimas V. Lukas, J. Goldschmidt, Paul Conkling, Keunchil Park, Diego Cortinovis, Filippo de Marinis, Achim Rittmeyer, Jyoti D. Patel, Joachim von Pa...> ;Lung Cancer. 2019 Feb 1
80 citations
Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
J. von Pawel, Rodolfo Bordoni, Miyako Satouchi, Louis Fehrenbacher, M. Cobo, J-Y. Han, Toyoaki Hida, Denis Moro-Sibilot, Paul Conkling, David R. Gandara, Achim Rittmey...> ;European Journal of Cancer. 2019 Jan 1
49 citations
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Michael R. Savona, Kathryn S. Kolibaba, Paul Conkling, Edwin C. Kingsley, John C. Morris, Robert M. Rifkin, Eric Laille, Amy Kellerman, Stacey M. Ukrainskyj, Qian Dong...> ;American Journal of Hematology. 2018 Sep 3
13 citations
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
Ralph V. Boccia, Alberto Bessudo, Richy Agajanian, Paul Conkling, Wael A. Harb, Hui Yang, Dawn E. Pinchasik, Amy S. Kimball, James R. Berenson> ;Clinical Lymphoma, Myeloma & Leukemia. 2017 Jul 1
5 citations
Acute promyelocytic leukemia following solid organ transplantation
Armin Rashidi, Paul Conkling, Stephen I. Fisher> ;Annals of Hematology. 2016 Jan 1
6 citations
A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancrea...
Steven J. Cohen, Mark M. Zalupski, Paul Conkling, Francis W. Nugent, Wen Wee Ma, Manuel Modiano, Rolan Pascual, Fa-Chyi Lee, Lucas Wong, Evan M. Hersh> ;American Journal of Clinical Oncology. 2015 Dec 24
19 citations
90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;European Journal of Cancer. 2015 Sep 1
8 citations
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors
Robert M. Jotte, Daniel D. Von Hoff, Fadi Braiteh, Donald A. Richards, David Smith, Lawrence Garbo, Joe Stephenson, Paul Conkling, Francisco Robert-Vizcarrondo, Jian C...> ;Investigational New Drugs. 2015 Feb 1
27 citations
A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer
Allen Lee Cohn, Michael Lahn, Kristen E. Williams, Ann Cleverly, Celine Pitou, Sunil Kadam, Mark W. Farmen, Durisala Desaiah, R. N. Raju, Paul Conkling, Donald A. Rich...> ;International Journal of Oncology. 2014 Dec 1
8 citations
A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
Paul Conkling, Nicholas J. Vogelzang, Hilary Wu, Shengyan Hong, Rajesh Narwal, Meina Liang, Fatemeh Tavakkoli, Naimish Pandya> ;Cancer Chemotherapy and Pharmacology. 2014 Aug 23
79 citations
A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eyas Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor N. Saleh, Donald Thornton> ;Clinical Cancer Research. 2014 Jul 1
50 citations
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cel...
David Smith, Paul Conkling, Donald A. Richards, John Nemunaitis, Thomas E. Boyd, Alain C. Mita, Guillaume de La Bourdonnaye, David Wages, Alice S. Bexon> ;Cancer Immunology, Immunotherapy. 2014 Apr 27
42 citations
Thrombosis in acute promyelocytic leukemia.
Armin Rashidi, Marc L. Silverberg, Paul Conkling, Stephen I. Fisher> ;Thrombosis Research. 2013 Apr 1
30 citations
A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
Hope E. Uronis, Johanna C. Bendell, Ivy Altomare, Gerard C. Blobe, S. David Hsu, Michael A. Morse, Herbert Pang, S. Yousuf Zafar, Paul Conkling, Justin Favaro, Christy...> ;The Oncologist. 2013 Mar 1
67 citations
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients w...
Robert C. Doebele, P. Conkling, A. M. Traynor, Gregory A. Otterson, Yihua Zhao, S. Wind, Peter Stopfer, Roselinde H. Kaiser, D.R. Camidge> ;Annals of Oncology. 2012 Aug 1
59 citations
Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
Leonard B. Saltz, Suprith Badarinath, Shaker R. Dakhil, Bryan Bienvenu, W. Graydon Harker, George Birchfield, Laurence K. Tokaz, David Barrera, Paul Conkling, Mark All...> ;Clinical Colorectal Cancer. 2012 Jun 1
Phase Ib/II study of eribulin mesylate administered in combination with gemcitabine/cisplatin as first-line therapy for locally advanced or metastatic bladder cancer: ...
Vogelzang NJ, Conkling P, Duran I, Maroto JP, Modiano M, De Leonardis P, Hodge JP, Lieberman R> ;J. Clin. Oncol.. 2012-02-10
14 citations
Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Nicholas J. Robert, Paul Conkling, Mark Allen O'Rourke, Paul R. Kuefler, Kristi J. McIntyre, Feng Zhan, Lina Asmar, Yanping Wang, Oluwatoyin O. Shonukan, Joyce O'Shaug...> ;Breast Cancer Research and Treatment. 2011 Feb 1
Join now to see all

Hospital Affiliations

Sentara Leigh HospitalNorfolk, Virginia
Chesapeake Regional Medical CenterChesapeake, Virginia
Sentara Norfolk General HospitalNorfolk, Virginia
Sentara Virginia Beach General HospitalVirginia Beach, Virginia

PaulRConklingMD

Dr. Conkling is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.